Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Complete Response” Letters Might Include Benefit-Risk Framework Discussion

Executive Summary

FDA official says idea could be helpful; meanwhile, sponsors and others remain concerned about the framework’s undefined decision-making methods.

You may also be interested in...



US FDA's Patrick Frey Joins List Of Agency Leadership Departures

Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.

FDA’s Benefit-Risk Framework Should Be Used Earlier In Development, Firms Say

Early discussions based on the framework could engender more efficient drug reviews and aid industry in decisions on clinical programs, BIO and PhRMA note in comments to the agency.

Regulatory Freelancing: Rare Disease Group Hopes To Shape FDA Guidance

EveryLife Foundation is working on a white paper that it hopes will inform FDA’s guidance clarifying accelerated approval and fast track pathways, which is mandated in FDASIA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel